Stock ORY ORYZON GENOMICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Official Publications Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Market Closed - BME
Other stock markets
 11:35:10 2024-05-03 am EDT 		5-day change 1st Jan Change
1.928 EUR +0.94% Intraday chart for Oryzon Genomics S.A. -3.60% +2.12%
Apr. 22 Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat CI
Apr. 08 ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer CI

Official Publications

No official publication found

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies
  1. Stock Market
  2. Equities
  3. ORY Stock
  4. News Oryzon Genomics S.A.
  5. Official Publications